Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Acne in dark skin is influenced by environmental factors and can lead to hyperpigmentation, with various treatment options available.

This report describes two cases of third degree scalp burns from hair highlighting treatments, highlighting that conservative treatments are associated with prolonged healing, while surgical and psychological interventions result in better outcomes.

This study developed and validated a precise RP-HPLC-PDA method for estimating finasteride in bulk and tablet forms, suitable for quality control use.

This study found that stem cell therapy significantly improved burn healing rates in animal models, with hair follicle stem cells showing particularly strong effects.

This review suggests that natural compounds, particularly hydrolates, may improve burn wound healing and counter antibiotic resistance through their anti-inflammatory, antioxidant, and antimicrobial properties, offering promising complementary interventions.

This case report highlights the successful use of platelet-rich plasma infiltration to treat vasopressin-induced bilateral foot digit gangrene in a 20-year-old female, suggesting its potential in stimulating angiogenesis and wound healing, though further research is necessary to assess its general efficacy.

This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

Infrared light might help treat stubborn alopecia areata.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study established an IRGDS model with diagnostic capability for alopecia areata, which may serve as an auxiliary marker for the condition.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study found that the STRIAA scoring tool provides a rapid and highly reliable assessment of alopecia areata severity, showing a significant correlation with the traditional SALT score, thus enhancing clinical evaluation in patients with this condition.

In this study, the researchers reported that ischemia-modified albumin and IMA/albumin levels may not effectively predict disease severity in patients with alopecia areata.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This study found that ischemia-modified albumin (IMA) may be a promising biomarker of oxidative stress in patients with alopecia areata, offering better potential compared to other oxidative stress markers.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.